1. Home
  2. VRTX vs TT Comparison

VRTX vs TT Comparison

Compare VRTX & TT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • TT
  • Stock Information
  • Founded
  • VRTX 1989
  • TT 1885
  • Country
  • VRTX United States
  • TT Ireland
  • Employees
  • VRTX N/A
  • TT N/A
  • Industry
  • VRTX EDP Services
  • TT Auto Parts:O.E.M.
  • Sector
  • VRTX Technology
  • TT Industrials
  • Exchange
  • VRTX Nasdaq
  • TT Nasdaq
  • Market Cap
  • VRTX 96.6B
  • TT 92.5B
  • IPO Year
  • VRTX 1991
  • TT N/A
  • Fundamental
  • Price
  • VRTX $410.82
  • TT $422.39
  • Analyst Decision
  • VRTX Buy
  • TT Hold
  • Analyst Count
  • VRTX 25
  • TT 13
  • Target Price
  • VRTX $493.64
  • TT $451.77
  • AVG Volume (30 Days)
  • VRTX 1.7M
  • TT 1.4M
  • Earning Date
  • VRTX 11-03-2025
  • TT 10-29-2025
  • Dividend Yield
  • VRTX N/A
  • TT 0.89%
  • EPS Growth
  • VRTX N/A
  • TT 24.76
  • EPS
  • VRTX 14.07
  • TT 12.60
  • Revenue
  • VRTX $11,418,800,000.00
  • TT $20,750,100,000.00
  • Revenue This Year
  • VRTX $10.90
  • TT $11.69
  • Revenue Next Year
  • VRTX $9.57
  • TT $7.53
  • P/E Ratio
  • VRTX $29.16
  • TT $33.59
  • Revenue Growth
  • VRTX 10.46
  • TT 10.20
  • 52 Week Low
  • VRTX $362.50
  • TT $298.15
  • 52 Week High
  • VRTX $519.88
  • TT $476.19
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 61.10
  • TT 56.36
  • Support Level
  • VRTX $400.74
  • TT $417.94
  • Resistance Level
  • VRTX $411.91
  • TT $430.23
  • Average True Range (ATR)
  • VRTX 8.84
  • TT 8.01
  • MACD
  • VRTX 3.92
  • TT 2.69
  • Stochastic Oscillator
  • VRTX 97.78
  • TT 75.22

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About TT Trane Technologies plc

Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The $20 billion company generates approximately 70% of its sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for over 80% of its revenue.

Share on Social Networks: